| Document |
Document Title |
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...
|
|
WO/2022/162153A1 |
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compoun...
|
|
WO/2022/160530A1 |
The present invention provides an anisomycin derivative represented by a general formula (I) or a pharmaceutically acceptable salt, solvate, and stereoisomer thereof. In the present invention, it is found that the anisomycin and derivati...
|
|
WO/2022/162157A1 |
The present invention relates to novel conjugated oligonucleotide compounds, which are suitable for therapeutic use. Additionally, the present invention provides methods of making these compounds, as well as methods of using such compoun...
|
|
WO/2022/164041A1 |
The present invention relates to a novel compound exhibiting anti-inflammatory activity, and the compound of the present invention plays a key role in the generation of pro-inflammatory cytokines, thereby having excellent inhibitory acti...
|
|
WO/2022/159980A1 |
Disclosed herein are compounds (e.g., pyrrole compounds, carboxy pyrroles, etc.), including pharmaceutical compositions that include one or more of such compounds (e.g., carboxy pyrroles). Also disclosed are methods of making carboxy pyr...
|
|
WO/2022/159955A1 |
The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). The compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in th...
|
|
WO/2022/156758A1 |
A novel amide pyrrole compound and a use thereof in drugs, in particular, a use thereof as drugs for treating and/or preventing hepatitis B virus infections or diseases caused by the hepatitis B virus infections. Specifically, the presen...
|
|
WO/2022/156827A1 |
The present invention relates to an allicin derivative, having the structure as shown in formula I, and a preparation method and use therefor, wherein R1 and R2 are respectively an alkyl group having 1 to 4 carbons, a cycloalkyl group, a...
|
|
WO/2022/158993A1 |
The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): Formula (2), or a salt thereof, wherein R1 is hydroge...
|
|
WO/2022/156693A1 |
A compound represented by formula I containing an N-(substituted sulfonyl) acetamide structure, a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and an application thereof as a viral protease inhibitor in the prepa...
|
|
WO/2022/159649A1 |
The present invention is related to the development of novel compounds and methods for the treatment and/or prevention of malaria. The compounds prevent the formation by the malaria parasite of the piasmodium surface anion channel (PSAC)...
|
|
WO/2022/153626A1 |
Provided is a simple method for manufacturing a heterocycle-containing amino acid compound. This heterocycle-containing amino acid compound is manufactured by a method including a step A wherein a compound represented by the formula (2) ...
|
|
WO/2022/145923A1 |
The present invention relates to a pharmaceutical composition which is for preventing or treating viral infections and contains a piperlongumine-based compound as an active ingredient. Specifically, the piperlongumine-based compound acco...
|
|
WO/2022/143610A1 |
Disclosed are novel amide pyrrole compounds and the use thereof in medicaments, especially the use thereof as a medicament for treating and preventing hepatitis B. In particular, the present invention relates to a compound as represented...
|
|
WO/2022/145707A1 |
The present invention provides a novel piperlongumine-based compound, and an immunomodulator and a health functional food for immunomodulation, which comprise the compound or a pharmaceutically acceptable salt or solvate thereof as an ac...
|
|
WO/2022/134260A1 |
A preparation method for biliverdin or a derivative thereof. Biliverdin or the derivative thereof is prepared from a compound represented by formula 2. Formula II represents a single bond or a double bond. Formula II at the positions rep...
|
|
WO/2022/139593A1 |
Method for the preparation of amidines of formula (I) or formula (II) Formula (I), Formula (II), in a one-pot reaction process, from amines and carboxylic acid derivatives, where neither the use of a solvent nor the use of a metal comple...
|
|
WO/2022/134261A1 |
A biliverdin compound, having a structural formula as shown in formula 1, wherein R is selected from one of hydrogen, C1-C5 alkyl, and benzyl. Formula II represents a double bond or a single bond, and said formulas II in positions A and ...
|
|
WO/2022/137913A1 |
The present invention provides: a maleimide resin and a maleimide compound which are characterized by being a product of maleimidization of a polyamine compound (C) which is a product of reaction between a plurality of aromatic monoamine...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/134262A1 |
Provided is a dipyrromethene-1-one compound having a structural formula as represented by formula 1, wherein R is selected from one of hydrogen, C1-C5 alkyl and benzyl; R1 is selected from one of phenylthio, phenylsulfinyl, phenylsulfony...
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/134259A1 |
The present invention provides a pyrrolinone compound of which the structural formula is as shown in formula 1. R1 is selected from one of: C1-C5 alkoxy groups, a benzyloxy group, C1-C5 alkyl groups, and a phenyl group; R2 and R3 are eac...
|
|
WO/2022/139594A1 |
Method for the preparation of two amides from one amidine in a one-pot conversion, where amides of formula (I) or formula (II) are formed. Formula (Ia) and Formula (Ib) Fornula (IIa) and Formula (IIb).Obtained amides and their useful app...
|
|
WO/2022/140269A1 |
Materials, methods, and systems for biorthogonal ligation of hydrogel labels to crosslinked-natural polymer hydrogels are provided. A heterobifunctional linker includes a peptide-reactive activated functional group on the heterobifunctio...
|
|
WO/2022/133040A1 |
Provided are kinases inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds or compositions, such as methods of treating a proliferation disorder, such as a cancer or a tumor, or in some em...
|
|
WO/2022/129327A1 |
The present invention relates to compounds having a structure of general formula (I), processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in ...
|
|
WO/2022/130411A1 |
The present invention relates to novel SMAC mimetic peptidomimetics useful for the treatment of proliferative diseases including cancer in mammals. The novel SMAC mimetics are prepared by incorporating (2S,5R)-5-(5-methylfuran-2-yl)pyrro...
|
|
WO/2022/133097A1 |
The disclosure provides processes for preparing spiro derivatives, in particular (2R,5S)-7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]p
yrimidin-2-yl]-1,7- diazaspiro[4.4]nonan-6-one, as well as intermediates for use in said proces...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
|
WO/2022/132650A1 |
Described herein is a prodrug of a transient receptor potential vanilloid 1 receptor (TRPV1) agonist for the treatment of pain.
|
|
WO/2022/129953A1 |
P33613WO1 93 ABSTRACT The disclosures herein relate to compounds of Formula (1'): or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders ...
|
|
WO/2022/132649A1 |
Provided herein are pharmaceutical formulations comprising a transient receptor potential vanilloid 1 receptor (TRPV1) agonist, or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/131364A1 |
Provided is a wavelength conversion member that comprises a wavelength conversion layer and a base member, wherein the wavelength conversion layer contains a pyrromethene derivative and at least one inorganic phosphor selected from the g...
|
|
WO/2022/121661A1 |
Disclosed in the present invention is an organic acid lithium amino acid salt. The organic acid lithium is one or more of lithium isobutyrate, lithium n-butyrate, lithium lactate, lithium citrate or lithium cholesterol; the amino acid is...
|
|
WO/2022/121317A1 |
Disclosed is a 1,1'-biphenyl-2,6-diphenolic compound and the use thereof. The 1,1'-biphenyl-2,6-diphenolic compound is a new compound, and has good biological activity. By means of in vitro tumor cell activity experiments, it was found t...
|
|
WO/2022/119090A1 |
The present invention relates to a compound, or pharmaceutically acceptable salts thereof, for inhibiting the activity of the 5-HT7 serotonin receptor represented by structural formula 1 or 2.
|
|
WO/2022/087422A9 |
The present disclosure relates to compounds of Formula (I'): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are use...
|
|
WO/2022/047128A9 |
The present disclosure provides methods and compositions useful for diagnosing and treating activated alternative pathway of complement in a human subject with a SARS-CoV-2 infection. Also provided are methods of treating an infection by...
|
|
WO/2022/112351A1 |
The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of sai...
|
|
WO/2022/110842A1 |
Disclosed are a crystal form A of levorotatory fluoropyrrolidone and a preparation method therefor. In a powder X-ray diffraction pattern of the crystal form A, the crystal form A has a characteristic peak at a diffraction angle 2θ, whe...
|
|
WO/2022/110916A1 |
A method for preparing a nitrogen-containing heterocyclic compound and a derivative thereof by means of an enzymatic-chemical cascade method, comprising: reacting an alcohol, an amine, an alcohol dehydrogenase, a flavin molecule and a co...
|
|
WO/2022/113850A1 |
Provided is a novel compound or a near-infrared absorbing material containing said compound. Provided is: a compound represented by formula I, formula II, formula III-1, or formula III-2; a salt thereof; a solvate thereof; or a near-in...
|
|
WO/2022/113814A1 |
Provided are: a radiation-sensitive resin composition able to exhibit satisfactory levels of sensitivity, LWR performance and CDU performance; a method for forming a pattern; and an onium salt compound. This radiation-sensitive resin com...
|
|
WO/2022/111202A1 |
Disclosed in the present invention are a 3,5-dimethyl-4-sulfone group-1H-pyrrole compound, a preparation method therefor, and a use thereof. The chemical structure is shown in formula I. R1 and R2 are H, methyl, ethyl or isopropyl; R3 is...
|
|
WO/2022/111500A1 |
Compounds shown in Formula (I), pharmaceutical compositions, and methods of using related to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M 3 antagonists, w...
|
|
WO/2022/109361A1 |
This disclosure relates to aryl amidines of Formula I and their use as fungicides.
|
|
WO/2022/109598A1 |
Provided herein are integrin inhibitors, compositions thereof, and methods of their uses. Crystalline forms of salts of the inhibitors are also described, along with methods of preparing the crystalline forms. X-ray powder diffraction da...
|
